Background: In Egypt, colorectal carcinoma (CRC) is the sixth common cancer in males and the fifth among females. Widely studied epigenetic event in colorectal carcinogenesis is the hypermethylation of CPG islands associated with regions of tumor –suppressor genes.CGI methylation-induced gene silencing occurs early and is functionally linked with carcinogenesis. KRAS and BRAF mutations have been associated with silencing of MGMT and MLH1 genes respectively. Method: The present study was performed to examine the quantitative gene expression of wild types of KRAS and BRAF and their corresponding epigenetic MGMT and MLH1 respectively to evaluate its role as tumour markers of CRC. We used colonic tissue biopsies of twenty six patients proven to have colorectal adenocarcinoma. For each patient we examine two samples, one from the colonic lesion and the other from adjacent normal colonic tissue. The methylation status of BRAF and KRAS was evaluated by methylation-specific qPCR (Methyl-Light). Results: Wild types of both BRAF and KRAS were expressed (100%, 26/26) at both malignant and normal adjacent tissues with high significant difference in malignant tissues than normal tissue. Quantitation of BRAF was more significant than KRAS. Epigenetic hypermethylation of MLH1 and MGMT were highly significant expressed at malignant tissues and there was a highly significant positive correlation between qPCR of wild types BRAF and KRAS and their corresponding epigenetic MLH1 and MGMT respectively. Conclusion: Our observations suggest that BRAF and KRAS epigenetic hypemethylation may contribute for diagnosis of colorectal carcinogenesis at an early stage and for proper follow up and prognosis.